Abstracts Archive - Page 1393 of 2425 - ACR Meeting Abstracts

Abstract Number: 2812 • 2017 ACR/ARHP Annual Meeting
Healthcare Resource Utilization and Costs in Patients with Systemic Lupus Erythematosus before and after Initiating Treatment with Intravenous Belimumab: A US Claims Database Analysis
Christopher F Bell¹, Julie Priest^2,3, Marni Stott-Miller⁴, Hong Kan⁵, Justyna Amelio⁶, Xue Song⁷, Brendan Limone⁷, Virginia Noxon⁷ and Karen H. Costenbader⁸, ¹GSK US Value, Evidence and Outcomes, Research Triangle Park, NC, ²GSK US Value, Evidence and Outcomes (at the time of Study)*, Research Triangle Park, NC, ³US Health Outcomes Durham, *ViiV Healthcare (Present), Durham, NC, ⁴GSK Real World Evidence & Epidemiology, Uxbridge, United Kingdom, ⁵Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁶GSK Real World Evidence & Epidemiology, Stevenage, United Kingdom, ⁷Truven Health Analytics, an IBM company, Ann Arbor, MI, ⁸Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Belimumab, an inhibitor of B lymphocyte stimulator, is approved in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard of care. There is…
Abstract Number: 2813 • 2017 ACR/ARHP Annual Meeting
Interferon-Induced APOL1 over-Expression Causes Autophagic Dysfunction and Mitochondrial Stress in Risk Variant-Carrying Endothelial Cells
Ashira Blazer¹, Sara Rasmussen², Androo Markham³, Shilpi Mehta-Lee⁴, Jill P. Buyon⁴ and Robert M. Clancy², ¹Division of Rheumatology, NYU School of Medicine, New York, NY, ²Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ³Medicine, NYU School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY
Background/Purpose: In SLE Apolipoprotein L1 (APOL1) risk variants (RV) associate with cardiovascular and end stage renal disease. APOL1 induction initially promotes cellular maintenance through autophagy;…
Abstract Number: 2814 • 2017 ACR/ARHP Annual Meeting
Interferon-β Production By B Cells Promotes B Cell Survival and Is Strongly Associated with Active Disease in African Americans with SLE
Jennie Hamilton¹, Qi Wu², PingAr Yang³, Bao Luo⁴, Shanrun Liu⁵, Jun Li⁶, Ignacio Sanz⁷, W. Winn Chatham⁸, Hui-Chen Hsu² and John D. Mountz⁹, ¹Medicine/Division of Clinical Immunology and Rhematology, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁵Biochemistry & Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁷Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA, ⁸Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁹University of Alabama at Birmingham, Department of Medicine, Birmingham, AL
Background/Purpose: Plasmacytoid dendritic cells are considered the main source of pathogenic IFN in SLE. However, recent work found that elevated serum type I IFN protein…
Abstract Number: 2815 • 2017 ACR/ARHP Annual Meeting
Pathological Roles By Siglec and Type I Interferons for the Development of Autoimmune Congenital Heart Block
Robert M. Clancy¹, Marc Halushka² and Jill P. Buyon¹, ¹NYU School of Medicine, New York, NY, ²Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Given that diseases associated with anti-SSA/Ro such as SLE and Sjögren’s syndrome associate with an upregulation of type I interferons, recent attention has focused…
Abstract Number: 2816 • 2017 ACR/ARHP Annual Meeting
Prediction of Connective Tissue Disease in an at-Risk Cohort Using a Novel Interferon Stimulated Gene Expression Score
Md Yuzaiful Md Yusof^1,2, Yasser M El-Sherbiny^1,3, Antonios Psarras¹, Elizabeth M.A. Hensor^1,4, Adewonuola Alase¹, Alaa Mohamed¹, Miriam Wittmann^1,4, Paul Emery^1,4 and Edward M Vital^1,4, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³Clinical Pathology dept., School of Medicine, Mansoura University, Mansoura, Egypt, ⁴NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Prediction of connective tissue disease in an at-risk cohort using a novel interferon stimulated gene expression scoreBackground/Purpose: A period of ANA positivity and other immune…
Abstract Number: 2817 • 2017 ACR/ARHP Annual Meeting
Expression Patterns of Interferon Induced Genes in Newborns Exposed to Ro/SSA Autoantibodies in Utero
Gudny Ella Thorlacius¹, Malin Hedlund¹, Margarita Ivanchenko¹, Vijole Ottosson¹, Amina Ossoinak¹, Linda Lagnefeldt¹, Lars Rönnblom², Sven-Erik Sonesson³, Maija-Leena Eloranta⁴ and Marie Wahren-Herlenius¹, ¹Unit of Experimental Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ³Pediatric Cardiology Unit, Department of Women´s and Children´s Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁴Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden
Background/Purpose: Women with Sjögren’s syndrome and autoantibodies against Ro/SSA are at risk for pregnancy complications, including neonatal lupus erythematosus (NLE) and a congenital heart block…
Abstract Number: 2818 • 2017 ACR/ARHP Annual Meeting
Gene Expression Analysis Demonstrates That Multiple Type 1 Interferons Are Involved in Lupus Pathogenesis
Michelle Catalina¹, Prathyusha Bachali², Sushma Madamanchi¹, Amrie Grammer¹ and Peter Lipsky¹, ¹Ampel BioSolutions LLC, Charlottesville, VA, ²Ampel BioSolutions LLC, Charlottesville, MA
Background/Purpose: A role for interferon (IFN) in lupus pathogenesis has been inferred from the prominent IFN gene signature (IGS) found in lupus peripheral blood. However,…
Abstract Number: 2819 • 2017 ACR/ARHP Annual Meeting
Association of Socioeconomic Status with Osteoarthritis-Induced Disability Progression
Divya Narayanan¹, Rebecca J. Cleveland², Joanne M. Jordan³, Eric Seaberg⁴ and Leigh F. Callahan¹, ¹Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Thurston Arthritis Research Center, University of North Carolina School of Medicine, Chapel Hill, NC, ³Thurston Arthritis Research Center, University of North CArolina at Chapel Hill, Chapel Hill, NC, ⁴Bloomberg School of Public Health, Johns Hopkins Unviersity, Baltimore, MD
Background/Purpose: Osteoarthritis (OA) is the number one chronic condition of the joints. Social determinants associated with disability progression due to OA are largely unknown. Efforts…
Abstract Number: 2820 • 2017 ACR/ARHP Annual Meeting
Disease Activity By the Sledai in Lupus Patients Who Self Report Sleep Disturbance and Sleep Impairment Using the Patient-Reported Outcomes Measurement Information System Instruments
Teresa Aberle¹, Rufei Lu², Sarah Cioli³, Stan Kamp¹, Wade DeJager¹, Stephen Apel⁴, Cristina Arriens⁵, Eliza Chakravarty⁶, Aikaterini Thanou¹, Joel M. Guthridge⁷, Joan T. Merrill⁸ and Judith A. James⁹, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Oklahoma Medical research af, Edmond, OK, ⁷Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, OKC, OK, ⁸Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Lupus patients commonly report sleep dysfunction, which is associated with upregulation of inflammatory cytokines in healthy people. Studies exploring relationships between self-reported sleep dysfunction…
Abstract Number: 2821 • 2017 ACR/ARHP Annual Meeting
A Multidisciplinary Telemedicine Program for Identification of Spondyloarthritis in Medically Underserviced Communities
Christopher Hawke¹, Laura Passalent¹, Nigil Haroon², Robert D Inman³ and Y. Raja Rampersaud⁴, ¹Allied Health, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ³Department of Immunology, University of Toronto, Toronto, ON, Canada, ⁴Arthritis Program, Krembil Research Institute, University Health Network, Torotno, ON, Canada
Background/Purpose: Early diagnosis is critical for optimal management of patients with inflammatory arthritis. Axial spondyloarthritis (AxSpA) has the longest delay in diagnosis among inflammatory joint…
Abstract Number: 2822 • 2017 ACR/ARHP Annual Meeting
A Randomized Controlled Effectiveness Trial of the Enhance-Fitness® Physical Activity Program in People with Arthritis
Dina L. Jones¹, Jennifer L. Eicher¹, Hannah M. Ludwick² and Kayéromi D. Gomez³, ¹Orthopaedics, West Virginia University, Morgantown, WV, ²Biostatistics, West Virginia University, Morgantown, WV, ³Office of Research, University of Illinois College of Medicine at Rockford, Rockford, IL
Background/Purpose: EnhanceFitness® (EF) is an evidence-based, community-delivered intervention for older adults; however, its effectiveness in people with arthritis is unknown. The purpose of this pragmatic,…
Abstract Number: 2823 • 2017 ACR/ARHP Annual Meeting
Preliminary Comparison of Patient-Centered Weight Loss Programs Starting before Versus after Knee Replacement
Christine Pellegrini^1,2, Rowland W. Chang³, Dorothy D. Dunlop⁴, David Conroy^1,5, Julia (Jungwha) Lee⁶, Linda VanHorn⁶, Bonnie Spring¹ and Kenzie Cameron⁷, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Exercise Science, University of South Carolina's Arnold School of Public Health, Columbia, SC, ³Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Center for Healthcare Studies, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Kinesiology, The Pennsylvania State University, University Park, PA, ⁶Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁷General Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Most patients risk gaining weight in the years after knee replacement, adding further concern to a population that is mostly overweight/obese prior to surgery.…
Abstract Number: 2824 • 2017 ACR/ARHP Annual Meeting
Sleep and Depression Mediate the Relationship between Pain and Cognitive Dysfunction in Lupus Patients
Teresa A. Lillis¹, Vanessa Tirone¹, Stacy Weinberg², Nisarg Gandhi³, Ailda Nika⁴, Winston Sequeira⁴, Stevan E. Hobfoll¹, Joel A. Block² and Meenakshi Jolly⁴, ¹Behavioral Sciences, Rush University Medical Center, Chicago, IL, ²Division of Rheumatology, Rush University Medical Center, Chicago, IL, ³Rush University Medical Center, Chicago, IL, ⁴Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Cognitive Dysfunction (CD) is seen among 20-80% of patients with Systemic Lupus Erythematosus (SLE) and adversely affects their quality of life and productivity. Pain,…
Abstract Number: 2825 • 2017 ACR/ARHP Annual Meeting
A Possible Environmental Origin for a Proportion of the Genetic Risk of Rheumatoid Arthritis and Systemic Lupus Erythematosus
John B. Harley¹, Xiaoting Chen¹, Mario Pujato², Daniel Miller¹, Avery Maddox¹, Carmy Forney³, Albert Magnusen³, Arthur Lynch¹, Kashish Chetal⁴, Masashi Yukawa⁵, Artem Barski⁶, Nathan Salomonis⁴, Kenneth Kaufman⁷, Leah C. Kottyan⁸ and Matthew Weirauch⁹, ¹Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Center of Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Center of Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Divisions of Allergy and Immunology and Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Divisions of Allergy and Immunology and Bioinformatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁸Center for Autoimmune Genomics and Etiology (CAGE), Division of Allergy and Immunology, Cincinnati Children's Hospital, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Center for Autoimmune Genomics and Etiology (CAGE) and Divisions of Biomedical Informatics and Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Nearly 150 genetic loci are convincingly associated with lupus (SLE) or rheumatoid arthritis (RA) and underlie their incompletely understood mechanisms of pathogenesis. Since 90%…
Abstract Number: 2826 • 2017 ACR/ARHP Annual Meeting
Fine-Mapping Identifies Causal Variants for RA and T1D in DNASE1L3, Sirpg, MEG3, TNFAIP3 and CD28/CTLA4 Loc
Harm-Jan Westra¹, Marta Martinez-Bonet², Suna Onengut³, Annette Lee⁴, Yang Luo¹, Nikola Teslovich¹, Jane Worthington⁵, Javier Martín⁶, TWJ Huizinga⁷, Lars Klareskog⁸, Solbritt Rantapää Dahlqvist⁹, Wei-Min Chen³, Aaron Quinlan¹⁰, John Todd¹¹, Stephen Eyre⁵, Peter Nigrovic², Peter Gregersen⁴, Stephen Rich³ and Soumya Raychaudhuri¹², ¹Division of Genetics and Rheumatology, Department of Medicine, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Department of Public Health Sciences, University of Virginia, Charlottesville, VA, ⁴The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, ⁵Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ⁶Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁹University of Umeå, Umeå, Sweden, ¹⁰Department of Human Genetics, University of Utah, Salt Lake City, UT, ¹¹JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, Wellcome Trust Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, ¹²Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: While genome-wide association studies have identified risk loci for rheumatoid arthritis and other autoimmune diseases, in very few instances have causal variants driving risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].